Calais J, Czernin J, Thin P, Gartmann J, et al. Safety of PSMA-Targeted Molecular Radioligand Therapy with (177)Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312). J Nucl Med 2021;62:1447-1456.
PMID: 34272322